Evaluation of the Efficacy of Early Bunching of a FF-PCC in Patients With Severe Traumatic Hemorrhage
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Feb 21, 2023
Trial Information
Current as of November 11, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a treatment called four-factor prothrombin complex (4F-PCC) in patients with severe traumatic bleeding. When someone experiences a major injury, they can lose a lot of blood, which can lead to serious complications and increase the risk of death. The researchers want to see if giving 4F-PCC early can help improve blood clotting and overall recovery for patients who are experiencing significant bleeding due to trauma.
To participate in this trial, individuals must be adults aged 18 to 79 who have suffered a severe injury (measured by a specific scoring system) and are bleeding actively. They should also be evaluated within three hours of their injury and expected to need a substantial amount of blood transfusions. However, certain people, such as those with a history of blood clots or severe head injuries, will not be eligible. Participants in the trial can expect to receive the treatment and be monitored closely to see how it affects their recovery. This could be an important step in finding better ways to treat patients with severe trauma and improve their chances of survival.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) The age of adult trauma patients ≥18 years, \< The 80 - year - old (2) ISS\> 16 (3) emergency preview class for 1 to 2; (4) after trauma \& lt; 3 hours; Trauma induced active bleeding; (5) blood consumption (ABC) score of 2 or more, or a preliminary assessment of blood loss \& gt; 1000ml or ≥4 units of red blood cells expected to be transfused
- Exclusion Criteria:
- • (1) history of anticoagulation and antiplatelet drugs (2) has a deep venous thromboembolism (VTE) and pulmonary embolism (PE) history (3) (4) on patients with severe head injury occurred cardiac arrest patients (5) lactation, pregnant women 6 Abdominal cavity viscera perforation surgical treatment in patients with 7) in patients with sepsis shock patients with all kinds of mental illness incapacitated pet-name ruby are unknown agent for informed consent.
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
yongan xu, doctor
Study Chair
Second Affiliated Hospital, School of Medicine, Zhejiang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials